Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-30T15:09:13.621Z Has data issue: false hasContentIssue false
  • English
  • Français

Adenosine 3′5′ cyclic monophosphate metabolism in patients with severe depressive illness1

Published online by Cambridge University Press:  09 July 2009

David B. Jarrett ,
Barbara Newell ,
Brian Davies  and
John P. Coghlan
David B. Jarrett*
Affiliation:
Department of Psychiatry, University of Melbourne, Australia
Barbara Newell
Affiliation:
Department of Psychiatry, University of Melbourne, Australia
Brian Davies
Affiliation:
Department of Psychiatry, University of Melbourne, Australia
John P. Coghlan
Affiliation:
Howard Florey Institute of Experimental Medicine and Physiology, Australia
*
2Address for correspondence: Dr D. B. Jarrett, NIAMDD/DB, Building 10, Room 8S-243, National Institute of Health, Bethesda, Maryland 20014, USA.
Get access Rights & Permissions [Opens in a new window]

Synopsis

The daily excretion of adenosine 3′5′ cyclic monophosphate (c-AMP) in a group of 19 patients with a severe depressive illness was found to be significantly decreased when compared with that from a group of euthymic patients being treated for other disorders in the same ward. The daily excretion of the depressed patients increased during the period of treatment and recovery from the illness. Treatment with a tricyclic antidepressant caused a greater increase than electroconvulsive treatment (ECT). There was no difference between the mean plasma c-AMP concentration of the depressed and euthymic groups. The mean CSF c-AMP concentration was not different from the mean plasma c-AMP concentration in 12 patients with severe depression. There was no direct correlation between the CSF and plasma concentrations within patients. It was concluded that there may be a reversible disturbance in the renal metabolism of c-AMP in patients with severe depression.

Type
Research Article
Information
Psychological Medicine , Volume 7 , Issue 1 , February 1977 , pp. 93 - 101
Copyright
Copyright © Cambridge University Press 1977

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

Address for reprints: Department of Psychiatry, University of Melbourne, P.O. Royal Melbourne Hospital, Victoria 3050, Australia.

References

REFERENCES

Adbullah, Y. H. & Hamadah, K. (1970). 3′5′ cyclic adenosine monophosphate in depression and mania. Lancet i, 378–381.Google Scholar
Berg, G. R. & Glinsman, W. H. (1970). Cyclic AMP in depression and mania. Lancet ii, 834.CrossRefGoogle Scholar
Blonde, L., Wehman, R. E. & Steiner, A. L. (1974). Plasma clearance rates and renal clearance of 3H labelled cyclic AMP and 3H labelled cyclic GMP in the dog. Journal of Clinical Investigation 53, 163–172.CrossRefGoogle ScholarPubMed
Broadus, A. E., Kaminsky, N. I., Hardman, J. G., Sutherland, E. W. & Liddle, G. W. (1970 a). Kinetic parameters and renal clearances of plasma adenosine 3′5′ monophosphate and guanosine 3′5′ monophosphate in man. Journal of Clinical Investigation 49, 2222–2236.CrossRefGoogle ScholarPubMed
Broadus, A. E., Kaminsky, N. I., Northcutt, R. C., Hardman, J. G., Sutherland, E. W. & Liddle, G. W. (1970 b). Effects of glucagon on adenosine 3′5′ monophosphate and guanosine 3′5′ monophosphate in human plasma and urine. Journal of Clinical Investigation 49, 2237–2245.CrossRefGoogle ScholarPubMed
Broadus, A. E., Hardman, J. G., Kaminsky, N. I., Ball, J. H., Sutherland, E. W. & Liddle, G. W. (1971). Extracellular cyclic nucleotides. Annals of the New York Academy of Sciences 185, 50–66.CrossRefGoogle ScholarPubMed
Brown, B. L., Salway, J. C., Albano, J. D. M., Hullin, R. P. & Ekins, R. P. (1972). Urinary excretion of cyclic AMP and manic-depressive psychosis. British Journal of Psychiatry 120, 405–408.CrossRefGoogle ScholarPubMed
Burrows, G. D., Davies, B. & Scoggins, B. A. (1972). Plasma concentration of nortriptyline and clinical response in depressive illness. Lancet ii, 619–623.CrossRefGoogle Scholar
Chase, L. R., Melson, G. L. & Aurbach, G. D. (1969). Pseudo-hypoparathyroidism: defective secretion of 3′5′ AMP in response to parathyroid hormone. Journal of Clinical Investigation 48, 1832–1844.CrossRefGoogle ScholarPubMed
Cramer, H., Goodwin, F. K., Post, R. M. & Bunney, W. E. (1972). Effects of probenecid and exercise on cerebrospinal fluid cyclic AMP in affective illness. Lancet i, 1346–1347.CrossRefGoogle Scholar
Cramer, H., Ng, L. K. Y. & Chase, T. N. (1973). Adenosine 3′5′ monophosphate in cerebrospinal fluid. Archives of Neurology 29, 197–199.CrossRefGoogle ScholarPubMed
Eccleston, D., Loose, R., Pullar, I. A. & Sugden, R. F. (1970). Exercise and urinary excretion of cyclic AMP. Lancet ii, 612.CrossRefGoogle Scholar
Edwards, O. M., Bayliss, R. I. S. & Millen, S. (1969). Urinary creatinine excretion as an index of the completeness of 24-hour urine collections. Lancet ii, 1165–1166.CrossRefGoogle Scholar
Exton, J. H., Lewis, S. B., Ho, R. J., Robinson, G. A. & Park, C. R. (1971). Role of cyclic AMP in the interaction of glucagon and insulin in the control of liver metabolism. Annals of the New York Academy of Sciences 185, 85–100.CrossRefGoogle ScholarPubMed
Goldberg, N. D., Larner, J., Sasko, H. & O'Toole, A. G. (1969). Enzymatic analysis of cyclic 3′5′ AMP in mammalian tissues and urine. Analytical Biochemistry 28, 523–544.CrossRefGoogle Scholar
Hamadah, K., Holmes, H., Barker, G. B., Hartman, G. C. & Parke, D. V. W. (1972). Effect of electric convulsive therapy on urinary excretion of 3′5′ cyclic adenosine monophosphate. British Medical Journal iii, 439–441.CrossRefGoogle Scholar
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56–62.CrossRefGoogle ScholarPubMed
Hardman, J. G., Davis, J. W. & Sutherland, E. W. (1969). Effects of some hormonal and other factors on the excretion of guanosine 3′5′ monophosphate and adenosine 3′5′ monophosphate in rat urine. Journal of Biological Chemistry 244, 6354–6362.CrossRefGoogle ScholarPubMed
Iversen, L. L. (1975). Dopamine receptors in the brain. Science 188, 1084–1089.CrossRefGoogle ScholarPubMed
Jarrett, D. B. (1975). Pituitary-adrenal function in psychiatric syndromes. Ph.D. Thesis, University of Melbourne.Google Scholar
Jarrett, D. B., Newell, B., Coghlan, J. P. & Scoggins, B. A. (1976). The plasma clearance rate of adenosine 3′5′ cyclic monophosphate in the sheep. Submitted.Google Scholar
Jenner, F. A., Sampson, G. A., Thompson, E. A., Somerville, A. R., Beard, N. A. & Smith, A. A. (1972). Manicdepressive psychosis and urinary excretion of cyclic AMP. British Journal of Psychiatry 121, 236–237.CrossRefGoogle ScholarPubMed
Moyle, W. R., Kong, Y. C. & Ramachandran, J. (1973). Steroidogenesis and cyclic adenosine 3′5′ monophosphate accumulation in rat adrenal cells. Journal of Biological Chemistry 248, 2409–2417.CrossRefGoogle ScholarPubMed
Naylor, G. J., Stansfield, D. A., Whyte, S. F. & Hutchinson, F. (1974). Urinary excretion of adenosine 3′5′ cyclic monophosphate in depressive illness. British Journal of Psychiatry 125, 275–279.CrossRefGoogle ScholarPubMed
Owen, P. & Moffat, A. C. (1973). Variation of cyclic AMP excretion with urine volume. Lancet ii, 1205.CrossRefGoogle Scholar
Paul, M. I., Ditzion, B. R. & Janowsky, D. S. (1970 a). Affective illness and c-AMP excretion. Lancet i, 88.CrossRefGoogle Scholar
Paul, M. I., Ditzion, B. R., Pauk, G. L. & Janowsky, D. S. (1970 b). Urinary cyclic AMP excretion in affective disorders. American Journal of Psychiatry 126, 1493–1497.CrossRefGoogle ScholarPubMed
Paul, M. I., Cramer, H. & Bunney, W. E. (1971 a). Urinary c-AMP in the switch process from depression to mania. Science 171, 300–303.CrossRefGoogle Scholar
Paul, M. I., Cramer, H. & Goodwin, F. K. (1971 b). Urinary cyclic AMP excretion in depression and mania. Archives of General Psychiatry 24, 327–333.CrossRefGoogle ScholarPubMed
Raabo, E. & Wallöe-Hansen, P. W. (1972). A routine method for creatinine avoiding deproteinization. Scandinavian Journal of Clinical and Laboratory Investigation 29, 297–301.CrossRefGoogle ScholarPubMed
Robinson, G. A., Coppen, A. J., Whybrow, P. C. & Prange, A. J. (1970). Cyclic AMP in affective disorders. Lancet ii, 1028–1029.CrossRefGoogle Scholar
Siegel, S. (1956). Non-Parametric Statistics for the Behavioural Sciences. McGraw-Hill: New York.Google Scholar
Sinanan, K., Keatinge, A. M. B., Beckett, P. G. S. & Love, W. C. (1975). Urinary cyclic AMP in ‘endogenous’ and ‘neurotic’ depression. British Journal of Psychiatry 126, 49–55.CrossRefGoogle ScholarPubMed
Somerville, A. R. (1973). Adenosine 3′5′ cyclic monophosphate and affective disorders. Biochemical Society Special Publication 1, 27–132.Google Scholar
Steiner, A. L., Parker, C. W. & Kipnis, D. M. (1970). The measurement of cyclic nucleotides by radioimmunoassay. Advances in Biochemical Psychopharmacology 3, 89–111.Google ScholarPubMed
Taylor, A. L., Davis, B. B., Parlson, L. G., Josimovich, J. B. & Mintz, D. H. (1970). Factors influencing the urinary excretion of 3′5′ adenosine monophosphate in humans. Journal of Clinical Endocrinology and Metabolism 30, 316–324.CrossRefGoogle ScholarPubMed
Wehman, R. E., Blonde, L. & Steiner, A. L. (1974). Sources of cyclic nucleotides in plasma. Journal of Clinical Investigation 53, 173–179.CrossRefGoogle Scholar
Williams, R. H., Barish, J. & Ensinck, J. W. (1972). Hormone effects upon cyclic nucleotide excretion in man. Proceedings of the Society for Experimental Biology and Medicine 139, 447–454.CrossRefGoogle ScholarPubMed